Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Vistagen Therapeutics Inc (VTGN) Common Stock USD0.001

Sell:$0.65 Buy:$0.72 Change: $0.13 (22.81%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$0.65
Buy:$0.72
Change: $0.13 (22.81%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$0.65
Buy:$0.72
Change: $0.13 (22.81%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

Contact details

Address:
343 Allerton Ave
SOUTH SAN FRANCISCO
94080-4816
United States
Telephone:
+1 (650) 5773600
Website:
https://www.vistagen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VTGN
ISIN:
US92840H2022
Market cap:
$30.26 million
Shares in issue:
43.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • H. Snodgrass
    President, Chief Scientific Officer, Director
  • Shawn Singh
    Chief Executive Officer, Director
  • Jerrold Dotson
    Chief Financial Officer, Vice President, Secretary
  • Mark McPartland
    Vice President, Corporate Development
  • Mark Smith
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.